Anti-Human EMB Antibody (SAA1846)

Catalog No.

RHN01101

Species reactivity

Human

Host species

Mouse

Isotype

IgG2a, kappa

Clonality

Monoclonal

Target

EMB, Embigin

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q6PCB8

Applications

ELISA

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

SAA1846

Optimization of a novel 2+2 BCMA x CD3 bispecific antibody for minimized cytokine release and potent efficacy., PMID:40465538

Exploring a novel approach to COPD treatment: benralizumab effect in an ex vivo 3-D model., PMID:40254172

First-in-human phase I study of EMB-02, a bispecific antibody targeting PD-1 and LAG-3 in patients with advanced solid tumors., PMID:40234667

Kaposi's sarcoma herpesvirus seroprevalence among blood donors in Uganda., PMID:40172229

Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis., PMID:40168091

Prevalence of transfusion transmitted infections by mode of donation and remuneration status among blood donors in Georgia, 2018-2023., PMID:40157049

Using Pharmacokinetic and Pharmacodynamic Analysis to Optimize the Dosing Regimens of Fanastomig (EMB-02) in Patients With Advanced Solid Tumors., PMID:40067130

Surveillance donor-specific antibody and pathologic antibody-mediated rejection testing in heart transplant patients in the contemporary era., PMID:39914762

Recombinant Anti-PF4 Antibodies Derived from Patients with Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT) Facilitate Research and Laboratory Diagnosis of VITT., PMID:39852782

The impact of high-risk cytogenetic abnormalities in extramedullary multiple myeloma in the era of novel agents: insights from a multicenter study., PMID:39695462

Association Between Peptide Antigen-Related Antibody Levels and the Short- and Long-Term Efficacy of Antipsychotic Treatment in Drug-Naïve First-Episode Schizophrenia Patients., PMID:39673496

Redefining Cardiac Antibody-Mediated Rejection With Donor-Specific Antibodies and Graft Dysfunction., PMID:39584219

A Novel Designed Anti-PD-L1/OX40 Bispecific Antibody Augments Both Peripheral and Tumor-Associated Immune Responses for Boosting Antitumor Immunity., PMID:39575565

Decreasing Endomyocardial Biopsy Frequency in Pediatric Heart Transplantation Using A Rejection Risk Prediction Score-A Single Center Study., PMID:39559942

Trends in new hepatitis C virus infections among repeat blood donors - Georgia, 2017-2023., PMID:39547544

Autoimmune Encephalitis and Paraneoplastic Neurologic Syndromes: A Nationwide Study on Epidemiology and Antibody Testing Performance., PMID:39467237

Histopathological Characteristics of Percutaneous Endomyocardial Biopsy in Heart Transplant Rejection Surveillance: A Single Center Experience., PMID:39457571

Post-hoc analyses from the ADAPT clinical study demonstrate aggregate sustained benefit of Efgartigimod in generalized myasthenia gravis., PMID:39426360

Pathologist interrater reliability and clinical implications of elevated donor-derived cell-free DNA beyond heart transplant rejection, on behalf of the GRAfT investigators., PMID:39424014

Clinical Utility of Donor-Derived Cell-Free DNA in Heart Transplant Recipients With Multi-Organ Transplants., PMID:39422086

Progress in Noninvasive Surveillance for Acute Rejection in Pediatric Heart Transplant Recipients: A Real-World Analysis of Donor-Derived Cell-Free DNA-Based Surveillance Protocol., PMID:39412485

Reference values of strain-derived myocardial work indices in heart transplant patients., PMID:39391531

Time to response with ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis., PMID:39373062

Current state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions., PMID:39324647

Donor-derived Cell-free DNA Evaluation in Pediatric Heart Transplant Recipients: A Single-center 12-mo Experience., PMID:39301559

Heart Transplant Rejection: From the Endomyocardial Biopsy to Gene Expression Profiling., PMID:39200392

Outcome-based Risk Assessment of Non-HLA Antibodies in Heart Transplantation: A Systematic Review., PMID:38796046

Structural biology of flavivirus NS1 protein and its antibody complexes., PMID:38777094

Histopathology, mRNA expression profile, and donor-derived cell-free DNA for assessment of rejection in pediatric heart transplantation., PMID:38528753

A gentler approach to monitor for heart transplant rejection., PMID:38380175

Relationship between donor-derived cell-free DNA and tissue-based rejection-related transcripts in heart transplantation., PMID:38373559

Monitoring of plasma circulating donor DNA reflects cardiac graft injury: Report of two cases., PMID:38357233

Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis., PMID:38318236

Donor-Specific Antibody Testing is an Effective Surveillance Strategy for High-Risk Antibody Mediated Rejection in Heart Transplant Patients in the Contemporary Era., PMID:38106112

Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study., PMID:37843174

Recurrent Mild Acute Rejections and Donor-specific Antibodies as Risk Factors for Cardiac Allograft Vasculopathy in a National Pediatric Heart Transplant Cohort., PMID:37745950

Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients., PMID:37721859

Organically Templated Uranyl Sulfates and Selenates: Structural Complexity and Crystal Chemical Restrictions for Isotypic Compounds Formation., PMID:37629201

Stage 4N neuroblastoma before and during the era of anti-GD2 immunotherapy., PMID:37602920

Morphological Changes in the Myocardium of Patients with Post-Acute Coronavirus Syndrome: A Study of Endomyocardial Biopsies., PMID:37443606

Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants., PMID:37433788

Antibodies Associated With Autoimmune Encephalitis in Patients With Presumed Neurodegenerative Dementia., PMID:37311646

SARS-CoV-2 seroprevalence among blood donors in Uganda: 2019-2022., PMID:37255467

Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results., PMID:36997799

Coronavirus Disease 2019 Convalescent Plasma Utilization in the United States: Data From the National Inpatient Sample., PMID:36987595

Cell-matrix interactions control biliary organoid polarity, architecture, and differentiation., PMID:36972396

The effect of opioids on the efficacy of immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck., PMID:36963232

Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019., PMID:36740590

Symptom Duration and Resolution With Early Outpatient Treatment of Convalescent Plasma for Coronavirus Disease 2019: A Randomized Trial., PMID:36722044

Soluble tumor endothelial marker 1 in heart failure with reduced ejection fraction: A pilot study., PMID:36588577

Document Download

Anti-Human EMB Antibody (SAA1846).pdf